Several inhibitors of the metalloenzyme carbonic anhydrase II have been the subject of extensive drug discovery research in the past because of their therapeutic potentials in areas including treatment of cancer, glaucoma prevention, osteoporosis and promotion of bone mineralization. This evidence concerns the gene CA2 and osteoporosis.